Afin de réduire sa dépendance à l’égard du marché mondial, Israël a demandé à des sociétés israéliennes de commencer à produire des kits de test. Le ministère de la Santé s’inquiète de la pénurie de tests corona , il n’en reste que quelques milliers en Israël,. « Nova Med » (1) devrait produire 5 000 marqueurs par jour à partir de demain. La possibilité de réduire la quantité de poche par patient est également à l’étude – de trois poche à deux, voire à une seule poche par patient. De plus, le ministère de la Santé envisage d’acheter et de fabriquer des respirateurs et d’ajouter ajouter des lits dans les unités de soins intensifs .
(1) Novamed, Ltd is a privately-owned Israeli life science company founded in December 1995. It operates in the In-Vitro Diagnostic (IVD) market from a 2,400 m2 facility in 19 Hartom St., Har Hotzvim, Jerusalem 9777518, Israel. Novamed, Ltd maintains a staff of about 80 employees engaged in research, development, manufacturing and sales. Novamed, Ltd is a leader in the development, manufacturing, and marketing of products used for diagnosing infectious diseases.
CEO – Dr. Emil Katz, Ph.D. in Immunology from the Weizmann Institute of Science, Israel. More than 30 years of experience in the healthcare field and strong entrepreneurial background; he successfully guided the development of three start-up companies including Diatech Diagnostics, which subsequently merged into Healthcare Technologies and is traded on NASDAQ.
Vice President & Marketing Manager – Dr. Gavriel Shalmiev, Ph.D. in medical parasitology from the Institute of Life Sciences of the Hebrew University, Israel.
Novamed Ltd has a range of innovative products, some of which are unique inventions that have no counterparts on the world market.
The regular production list of Novamed Ltd consists of more than 250 different items.
